- NCT06561685 Lung Cancer Clinical Trial | Lilly Oncology
Investigate NCT06561685 Lung Cancer Clinical Trial Stay informed on trial status, patient eligibility, and inclusion criteria
- Pembrolizumab and Cisplatin and Carboplatin in Advanced Solid Tumor and . . .
ICH GCP US Clinical Trials Registry Clinical Trial NCT06561685 A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors October 17, 2025 updated by: Eli Lilly and Company
- Abstract CT109: A first-in-human phase 1 study of LY4050784, an oral . . .
This is a first-in-human, phase 1a b open-label, multicenter study of LY4050784, an oral, potent and selective SMARCA2 inhibitor, in patients (pts) with advanced solid tumors with SMARCA4 alterations (NCT06561685)
- CLINICAL TRIAL NCT06561685 - UChicago Medicine
The main purpose of this study is to find out whether the study drug, LY4050784, is safe, tolerable and effective in participants alone or in combination with other anticancer agents
- CT109 Background A first-in-human This is a first-in-human, phase 1a b . . .
This is a first-in-human, phase 1a b open-label, multicenter study of LY4050784, an oral, potent and selective SMARCA2 inhibitor, in patients with advanced solid tumors with SMARCA4 alterations (NCT06561685)
- University of California Health Solid Tumor Trial: LY4050784 in . . .
An Open-label, Multicenter Study of LY4050784, a Selective SMARCA2 BRM Inhibitor, in Advanced Solid Tumor Malignancies With SMARCA4 BRG1 Alterations
- A Phase 1 Study of LY4050784 in People With Advanced Solid Tumors
Researchers want to find the best dose of LY4050784 to treat advanced solid tumors The people in this study have cancer that cannot be cured with standard therapies Their tumors also have a mutation (change) in the SMARCA4 and or BRG1 genes, which play a role in cancer growth LY4050784 targets cancer cells that make a gene called SMARCA2 BRM
- Trial | NCT06561685
Trial | NCT06561685 Report issue Study Overview Title A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors Official Title An Open-label, Multicenter Study of LY4050784, a Selective SMARCA2 BRM Inhibitor, in Advanced Solid Tumor Malignancies With SMARCA4 BRG1 Alterations Snapshot Phase Phase 1 Lead Sponsor Eli Lilly
|